News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
onvista.de Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Vice President, Investor Relations - Ashley StocktonPresident and Chief Executive Officer - Fred BurkeChief Operating Officer - David MorrisChief Financial Officer - Will Mudd TAKEAWAYS Revenue -- $351.8 …
Macy's has launched an exclusive Disney Sorcerer's Apprentice Mickey collection to celebrate Mickey's appearance as a giant balloon in the 100th Macy's Thanksgiving Day Parade. The collection features fashion, accessories, and collectibles from various brands, including Loungefly, Citizen, Crocs, and Swarovski. Items include headbands, …
This article focuses on the "Price to book forward" financial metric for Humacyte, Inc., traded on NASDAQ under the symbol HUMAW. It provides a snapshot of this financial data point within the context of the company's financial overview on a trading platform. The content …
Disney's Sorcerer's Apprentice Mickey Mouse will debut as a new giant character balloon in the 100th Macy's Thanksgiving Day Parade. This marks a continuation of Disney's long history with the parade, which began in 1934 with the first Mickey Mouse balloon. To celebrate this …
H.C. Wainwright has reiterated its Buy rating for Humacyte (HUMA.US), maintaining a price target of $4. This continued positive outlook from the analyst firm suggests confidence in the company's future performance.
Benchmark has lowered its price target for Humacyte (NASDAQ:HUMA) to $1.00 from $2.00, while maintaining a "speculative buy" rating, implying a potential 51% upside. This adjustment comes after Humacyte missed Q2 earnings expectations, reporting a loss of $0.16 per share against an estimated $0.11 …
Humacyte (HUMA) announced stronger Phase 3 dialysis access data for its acellular tissue engineered vessel in female patients, outperforming the standard of care. The company plans to submit a supplemental Biologics License Application based on these results and has also received FDA acceptance for …
Guardian Pharmacy Services has opened its first Kentucky location, Guardian Pharmacy of Kentucky, in Lexington. This new long-term care pharmacy will serve residents in various care settings across the state. The expansion aims to meet increasing demand for LTC pharmacy services in Kentucky, combining …
Key Points Costco's value pricing continues to attract and retain members. The company has perfected a different business model. It has room to expand.10 stocks we like better than Costco Wholesale › Investors often face choices. Sometimes, it comes down to two good stocks. …
Sharemaestro market context Trend signal active 52 weeks +72.6% · Next-week setup negative 39.1%Humacyte (HUMA) is in focus after its Q2 2026 earnings report, which showed modest revenue and a significant quarterly loss, compounded by a Nasdaq minimum bid price notice and interim Phase III dialysis trial data. Despite a fair value estimate of $4.00, suggesting it's …
Humacyte, Inc. (HUMA) reported a Q2 loss of $0.16 per share, missing the Zacks Consensus Estimate of a $0.1 loss, and revenues of $0.41 million, falling short of estimates by 70.79%. The company's shares have dropped 26.1% year-to-date, and it currently holds a Zacks …
Humacyte (HUMA [https://seekingalpha.com/symbol/HUMA]) shares fell 15% after the biotechnology company reported a wider-than-expected [https://seekingalpha.com/news/4631382-humacyte-gaap-eps-of--016-misses-by-006-revenue-of-041m-misses-by-07m] second-quarter loss and revenue below estimates. GAAP loss per share was $0.16, missing consensus by 6 cents, while revenue of $0.41 million fell $0.7 million short of expectations. Humacyte said …
Humacyte reported its Q2 earnings, highlighting commercial sales growth for its SYMVESS product and plans for a supplemental BLA submission for dialysis access. The company also detailed positive interim data from its V012 Phase III trial for dialysis patients and announced the initiation of …
Humacyte missed analyst expectations for Q2 2026 revenue and EPS, causing its shares to fall over 10% in premarket trading. Despite the financial miss, the company highlighted progress in its commercial rebuild for SYMVESS, significant clinical trial results for its ATEV in dialysis access, …
Emergency responders investigated a reported bomb threat at the Macy’s Distribution Center in China Grove, N.C. on Wednesday morning. Carson High School was closed as a precaution, and regional bomb squads and K-9 teams were on scene. Officials declared the incident concluded by 9:45 …
Humacyte announced its second-quarter 2026 results, reporting product revenue of $0.4 million and a net loss of $36.8 million, with $80.3 million in cash. The company also shared positive interim Phase 3 results for its ATEV in female dialysis patients, planning a supplemental BLA …
This article from Investing.com announces that Humacyte Inc. has filed a Form 8K on August 12. The brief news item includes the company's stock symbol HUMA and notes its current price performance. No further details about the content of the Form 8K are provided.
* Humacyte press release [https://seekingalpha.com/pr/20616207-humacyte-announces-second-quarter-2026-financial-results-and-provides-business-update] (HUMA [https://seekingalpha.com/symbol/HUMA]): Q2 GAAP EPS of -$0.16 misses by $0.06. * Revenue of $0.41M (+36.7% Y/Y) misses by $0.7M. MORE ON HUMACYTE * Humacyte, Inc. (HUMA) Discusses V012 Study Top-Line Results for Engineered Vessel in Dialysis Access Transcript [https://seekingalpha.com/article/4915163-humacyte-inc-huma-discusses-v012-study-top-line-results-for-engineered-vessel-in-dialysis] …
A bomb threat was reported at the Macy's distribution center in China Grove, prompting an evacuation of the facility. Emergency services responded, and after a thorough search, no explosives were found, and the scene was declared clear.
Guardian Pharmacy Services (NYSE:GRDN) saw its stock price drop by 5.5% on Tuesday, trading at approximately $39.19 with significantly lower than average trading volume. Despite this downturn, analyst sentiment remains positive with a "Moderate Buy" consensus and an average price target of $43.83, following …
Humacyte Inc (HUMA) is scheduled to release its Q2 2026 earnings on August 12, 2026, with revenue expected at $1.12 million and an EPS of $-0.1. Analysts anticipate full-year 2026 revenue of $6.35 million and EPS of $-0.34. Despite previous revenue estimate declines, earnings …
This story was originally published on FSR. To receive daily news and insights, subscribe to our free daily FS Insider. Like winding rivers that lead to the same lake, five women who chose wildly different career paths all arrived as leaders at a booming …
Sharemaestro market context Trend signal active 52 weeks +72.6% · Next-week setup negative 39.1%Janus Henderson Group PLC significantly reduced its stake in Guardian Pharmacy Services, Inc. by 72.1% in the first quarter, selling 33,674 shares and retaining 13,000 shares valued at $490,000. Despite this reduction and a recent 6.3% trading decline, Guardian Pharmacy Services reported strong quarterly …
Dimensional Fund Advisors LP significantly increased its stake in Guardian Pharmacy Services (NYSE:GRDN) by 200%, acquiring an additional 139,070 shares to bring its total to 208,594 shares valued at $7.855 million. Other institutional investors also boosted their holdings, with Jennison Associates LLC increasing its …
Eight brokerages have given Humacyte, Inc. (NASDAQ:HUMA) a consensus recommendation of "Moderate Buy," with one analyst issuing a sell rating and seven a buy rating. The average one-year price target is $6.25. Insider activity shows a sale by Shamik J. Parikh and a purchase …
Macy's (M) ended the recent trading session at $24.90, demonstrating a -1.97% change from the preceding day's closing price. This change lagged the S&P 500's daily loss of 0.06%. Meanwhile, the Dow experienced a drop of 0.11%, and the technology-dominated Nasdaq saw a decrease …
Sharemaestro market context Trend signal active 52 weeks +72.6% · Next-week setup negative 39.1%Kahn Swick & Foti, LLC (KSF) is continuing its investigation into Humacyte, Inc. regarding potential breaches of fiduciary duties by its officers and directors and violations of state or federal laws. This follows an FDA Form 483 inspection revealing violations at Humacyte's Durham facility …
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Macy's stock has delivered a strong 117.7% return over the past year, yet current …
Sharemaestro market context Trend signal active 52 weeks +72.6% · Next-week setup negative 39.1%Search by ticker symbol or company name and select a result to open its chart.